A Phase II Trial of Rituximab in Combination with Pegfilgrastim in Patients with Indolent B-Cell Non-Hodgkin ’s Lymphoma

This phase 2 study demonstrates that augmenting neutrophil function by addition of pegfilgrastim can potentiate the clinical activity of rituximab in indolent B-cell non-Hodgkin ’s lymphomas (B-NHL) while retaining its excellent safety profile. Strategies to boost the innate immune system such as this combination warrant further study, especially in the frail, elderly population where therapeutic options are limited due to poor tolerance.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research